Fiscal Year: January - December
Celldex Therapeutics, Inc. (CLDX), listed on the NASDAQ, has a market capitalization of $2.22B. As of Nov 06, 2026, the stock is trading at $28.24 per share@else an unavailable price , offering investors a clear view of its current market value. Celldex Therapeutics, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of N/A , investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Celldex Therapeutics, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
DCF analysis data is not yet available for Celldex Therapeutics, Inc. (CLDX). A fair value is shown for companies with at least three years of reported free cash flow and a positive typical free cash flow margin. Banks, insurers and REITs need a different valuation model and are not covered yet.
The proprietary SS Score for Celldex Therapeutics, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Celldex Therapeutics, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Celldex Therapeutics, Inc. is N/A , offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Celldex Therapeutics, Inc. (CLDX) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Celldex Therapeutics, Inc. (CLDX) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Celldex Therapeutics, Inc. (CLDX) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Celldex Therapeutics, Inc.. To access the full SS Score, consider upgrading your subscription.
Celldex Therapeutics, Inc. is a significant player in the industry sector, with a market capitalization of $2.22B and a competitive P/E ratio of N/A . Investors should compare these metrics with industry peers to gauge whether Celldex Therapeutics, Inc. is outperforming or underperforming within its sector.
16:50 EST Celldex (CLDX) files automatic mixed securities shelf
HAMPTON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming investor conferences: The Guggenheim 3rd Annua...
H.C. Wainwright analyst Joseph Pantginis says the Celldex (CLDX) bear case is trying “death by a thousand cuts.” Concerns are bouncing from one adverse event to another, the analyst tells…
Leerink analyst Thomas Smith raised the firm’s price target on Celldex (CLDX) to $88 from $70 and keeps an Outperform rating on the shares following the company’s investor call to…
Morgan Stanley raised the firm’s price target on Celldex (CLDX) to $57 from $50 and keeps an Overweight rating on the shares. Barzolvolimab demonstrated best-in-disease efficacy in EMBARQ-CSU, while i...
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Celldex (CLDX) to $64 from $42 and keeps a Buy rating on the shares after the company announced that…
Celldex Therapeutics said on Tuesday its experimental drug for a skin disease met the main and secondary goals of two late-stage trials.
Celldex (CLDX) reported positive topline results from the company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria, or ...
Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSU EMBARQ-CSU1 and -CSU2 met primary and all key secondary...
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Celldex (CLDX) to $50 from $46 and keeps an Overweight rating on the shares ahead of topline data from…
HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Septe...
Morgan Stanley raised the firm’s price target on Celldex (CLDX) to $46 from $40 and keeps an Overweight rating on the shares.
Barclays raised the firm’s price target on Celldex (CLDX) to $53 from $48 and keeps an Overweight rating on the shares post the Q2 report. The firm is positive on…
Wells Fargo raised the firm’s price target on Celldex (CLDX) to $72 from $48 and keeps an Overweight rating on the shares. While the Street is modeling a high probability…
Cantor Fitzgerald lowered the firm’s price target on Celldex (CLDX) to $61 from $67 and keeps an Overweight rating on the shares. Celldex’s Phase 2 barzolvolimab trial in prurigo nodularis…
Wells Fargo lowered the firm’s price target on Celldex (CLDX) to $48 from $54 and keeps an Overweight rating on the shares. While the firm removes PN from its model,…
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.
